BACKGROUND: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG). METHODS: Patients with recurrent HGG were treated with oral panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. The primary endpoint was a 6-month progression-fee survival (PFS6) rate for participants with recurrent glioblastoma (GBM). Patients with recurrent anaplastic glioma (AG) were evaluated as an exploratory arm of the study. RESULTS: At interim analysis, the GBM arm did not meet criteria for continued accrual, and the GBM arm was closed. A total of 24 patients with GBM were accrued prior to closure. The PFS6 rate was 30.4% (95%, CI 12.4%-50.7%), median PFS was 5 months (range, 3-9 months), and median overall survival (OS) was 9 months (range, 6-19 months). Accrual in the AG arm continued to completion, and a total of 15 patients were enrolled. The PFS6 rate was 46.7% (range, 21%-73%), median PFS was 7 months (range, 2-10 months), and median OS was 17 months (range, 5 months-27 months). CONCLUSIONS: This phase II study of panobinostat and bevacizumab in participants with recurrent GBM did not meet criteria for continued accrual, and the GBM cohort of the study was closed. Although it was reasonably well tolerated, the addition of panobinostat to bevacizumab did not significantly improve PFS6 compared with historical controls of bevacizumab monotherapy in either cohort.
BACKGROUND:Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG). METHODS:Patients with recurrent HGG were treated with oral panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. The primary endpoint was a 6-month progression-fee survival (PFS6) rate for participants with recurrent glioblastoma (GBM). Patients with recurrent anaplastic glioma (AG) were evaluated as an exploratory arm of the study. RESULTS: At interim analysis, the GBM arm did not meet criteria for continued accrual, and the GBM arm was closed. A total of 24 patients with GBM were accrued prior to closure. The PFS6 rate was 30.4% (95%, CI 12.4%-50.7%), median PFS was 5 months (range, 3-9 months), and median overall survival (OS) was 9 months (range, 6-19 months). Accrual in the AG arm continued to completion, and a total of 15 patients were enrolled. The PFS6 rate was 46.7% (range, 21%-73%), median PFS was 7 months (range, 2-10 months), and median OS was 17 months (range, 5 months-27 months). CONCLUSIONS: This phase II study of panobinostat and bevacizumab in participants with recurrent GBM did not meet criteria for continued accrual, and the GBM cohort of the study was closed. Although it was reasonably well tolerated, the addition of panobinostat to bevacizumab did not significantly improve PFS6 compared with historical controls of bevacizumab monotherapy in either cohort.
Authors: Mitomu Kioi; Hannes Vogel; Geoffrey Schultz; Robert M Hoffman; Griffith R Harsh; J Martin Brown Journal: J Clin Invest Date: 2010-02-22 Impact factor: 14.808
Authors: J Drappatz; E Q Lee; S Hammond; S A Grimm; A D Norden; R Beroukhim; M Gerard; D Schiff; A S Chi; T T Batchelor; L M Doherty; A S Ciampa; D C Lafrankie; S Ruland; S M Snodgrass; J J Raizer; P Y Wen Journal: J Neurooncol Date: 2011-10-08 Impact factor: 4.130
Authors: Hasan C Ugur; Naren Ramakrishna; Lorenzo Bello; Lata G Menon; Seung-Ki Kim; Peter M Black; Rona S Carroll Journal: J Neurooncol Date: 2007-02-20 Impact factor: 4.130
Authors: Thomas Asklund; Samuel Kvarnbrink; Camilla Holmlund; Carl Wibom; Tommy Bergenheim; Roger Henriksson; Håkan Hedman Journal: Anticancer Res Date: 2012-07 Impact factor: 2.480
Authors: Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Vinay K Puduvalli; Jing Wu; Ying Yuan; Terri S Armstrong; Elizabeth Vera; Jimin Wu; Jihong Xu; Pierre Giglio; Howard Colman; Tobias Walbert; Jeffrey Raizer; Morris D Groves; David Tran; Fabio Iwamoto; Nicholas Avgeropoulos; Nina Paleologos; Karen Fink; David Peereboom; Marc Chamberlain; Ryan Merrell; Marta Penas Prado; W K Alfred Yung; Mark R Gilbert Journal: Neuro Oncol Date: 2020-10-14 Impact factor: 12.300
Authors: Roberto Jose Diaz; Sheikh Ali; Mehreen Gull Qadir; Macarena I De La Fuente; Michael E Ivan; Ricardo J Komotar Journal: J Neurooncol Date: 2017-05-19 Impact factor: 4.130